Key result
Higher subcutaneous fat index linked to improved survival in men with castration-resistant prostate cancer.
Why the study?
Does subcutaneous fat distribution predict radiographic progression-free and cancer specific survival in men with castration resistant prostate cancer?
Observational
Does subcutaneous fat distribution predict radiographic progression-free and cancer specific survival in men with castration resistant prostate cancer?
Subcutaneous fat index determined by CT may serve as an objective prognostic factor for survival in men with castration resistant prostate cancer.
Answers are grounded in this paper and cite their sources.
Adiposity measures should not inform prognosis in castration-resistant prostate cancer; hypothesis-generating and requires prospective validation.
PURPOSE: The relationship between body fat distribution and survival remains unclear in patients with castration resistant prostate cancer treated with docetaxel and androgen receptor axis targeted agents. We investigated whether body composition parameters could predict radiographic progression-free and cancer specific survival in patients with castration resistant prostate cancer. MATERIALS AND RESULTS: or greater had better 1-year progression-free and 2-year cancer specific survival (p = 0.009 and 0.021, respectively). CONCLUSIONS: at diagnosis. The subcutaneous fat index determined by computerized tomography data could serve as a useful objective prognostic factor to discuss patient therapeutic options. Further studies are needed to define the roles of each body composition parameter in relation to pharmacokinetics and oncologic outcome.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2018) conducted an observational in Castration resistant prostate cancer. Subcutaneous fat index vs. Lower subcutaneous fat index was evaluated on 1-year radiographic progression-free and 2-year cancer specific survival (p=0.009 and 0.021). A higher subcutaneous fat index was associated with better 1-year progression-free and 2-year cancer-specific survival (p=0.009 and p=0.021) in men with castration-resistant prostate cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: